Drug Trial Radar · NCT07403188
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Nov 24, 2025
Primary completion
Jan 2041
Study completion Jan 2041
Sponsor
- Lead sponsor
- Kyverna TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Conditions
- Refractory Lupus Nephritis
- Myasthaenia Gravis
- Stiff Person Syndrome
- Rheumatoid Arthritis (RA)
- Multiple Sclerosis
- Dermatomyositis
- Systemic Sclerosis (SSc)
Interventions
KYV-101Drug
Autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) product.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events (AEs) as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
- Number of participants with new or recurrent malignancies as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
- Number of participants with new or exacerbation of a pre-existing neurologic disorder as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
- Number of participants with new or exacerbation of a prior rheumatologic or other autoimmune disorder as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
- Number of participants with new hematologic disorders as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
- Number of participants with new infections as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
- Number of participants with positive Replication-Competent Lentivirus (RCL) laboratory test results through Year 5 of long-term follow-up (LTFU).Time frame: Up to 5 years from study entry
- Number of participants with positive Chimeric Antigen Receptor (CAR) laboratory test results through Year 5 of long-term follow-up (LTFU).Time frame: Up to 5 years from study entry
- Number of participants with positive Anti-Drug-Antibody (ADA) laboratory test results through Year 5 of long-term follow-up (LTFU).Time frame: Up to 5 years from study entry
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Colorado, Denver
Denver, Colorado · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.